# Positron#0 emission#1 tomography#2 in#3 a#4 case#5 of#6 intracranial#7 hemangiopericytoma#8 .#9

c1:[positron_emission_tomography#0,in_a_case_of#3,intracranial_hemangiopericytoma#7]
stmt1 = c1

# Due#0 to#1 the#2 low#3 prevalence#4 of#5 hemangiopericytomas#6 (#7 HPCs#8 )#9 ,#10 data#11 on#12 the#13 biophysiological#14 characteristics#15 of#16 this#17 tumor#18 are#19 rare#20 .#21

f1:[{NIL#-1:data#11},are_rare#19,NIL]
c2:[NIL,due_to#0,{hemangiopericytomas#6:low_prevalence#3}]
c3:[NIL,due_to#0,{hpcs#8:low_prevalence#3}]
c4:[{NIL#-1:data#11},on#12,{tumor#18:biophysiological_characteristics#14}]
stmt2 = f1 c2 c3 c4

# Positron#0 emission#1 tomography#2 (#3 PET#4 )#5 demonstrated#6 a#7 sixfold#8 increased#9 uptake#10 of#11 [#12 11C#13 ]#14 methionine#15 and#16 hyperperfusion#17 in#18 the#19 HPC#20 ,#21 whereas#22 glucose#23 utilization#24 was#25 decreased#26 in#27 this#28 area#29 .#30

f2:[positron_emission_tomography#0,demonstrated#6,NIL]
f3:[sixfold#8,increased#9,{[_11c_]_methionine#12:uptake#10}]
f4:[sixfold#8,increased#9,{hyperperfusion#17:uptake#10}]
f5:[glucose_utilization#23,was_decreased_in#25,{NIL#-1:area#29}]
c5:[hyperperfusion#17,in#18,hpc#20]
stmt3 = f2 f3 f4 f5 c5

# This#0 low#1 glucose#2 utilization#3 is#4 in#5 contrast#6 to#7 the#8 high#9 [#10 11C#11 ]#12 methionine#13 uptake#14 and#15 the#16 malignancy#17 of#18 these#19 tumors#20 .#21

f6:[low_glucose_utilization#1,is_in_contrast_to#4,{tumors#20:high_[_11c_]_methionine_uptake#9}]
f7:[low_glucose_utilization#1,is_in_contrast_to#4,{tumors#20:malignancy#17}]
stmt4 = f6 f7

# The#0 characteristics#1 of#2 HPCs#3 in#4 PET#5 described#6 herein#7 for#8 the#9 first#10 time#11 offer#12 additional#13 diagnostic#14 criteria#15 and#16 may#17 help#18 especially#19 to#20 differentiate#21 these#22 tumors#23 from#24 meningiomas#25 .#26

f8:[{hpcs#3:characteristics#1},offer#12,additional_diagnostic_criteria#13]
f9:[{hpcs#3:characteristics#1},may_help_especially_to_differentiate#17,tumors#23]
c6:[hpcs#3,in#4,pet_described_herein#5]
c7:[tumors#23,from#24,meningiomas#25]
stmt5 = f8 f9 c6 c7

# Thyrotropin#0 receptor#1 :#2 a#3 role#4 for#5 thyroid#6 tumourigenesis#7 ?#8

f10:[thyrotropin_receptor#0,a_role_for#3,thyroid_tumourigenesis#6]
stmt6 = f10

# Human#0 thyroid#1 tumours#2 represent#3 an#4 example#5 of#6 the#7 interplay#8 of#9 genetic#10 and#11 non#12 genetic#13 carcinogenesis#14 .#15

f11:[human_thyroid_tumours#0,represent#3,{genetic#10:interplay#8}]
f12:[human_thyroid_tumours#0,represent#3,{non_genetic_carcinogenesis#12:interplay#8}]
stmt7 = f11 f12

# Recently#0 ,#1 genetic#2 abnormalities#3 in#4 the#5 elements#6 of#7 the#8 Thyrotropin#9 receptor#10 (#11 TSH#12 -#13 R#14 )#15 dependent#16 cAMP#17 regulatory#18 cascade#19 have#20 been#21 found#22 to#23 be#24 involved#25 both#26 in#27 benign#28 and#29 malignant#30 thyroid#31 tumours#32 .#33

f13:[genetic_abnormalities#2,have_been_found_to_be_involved_both_in#20,benign#28]
f14:[genetic_abnormalities#2,have_been_found_to_be_involved_both_in#20,malignant_thyroid_tumours#30]
c8:[genetic_abnormalities#2,in#4,{thyrotropin_receptor_(_tsh_-_r_)_dependent_camp_regulatory_cascade#9:elements#6}]
stmt8 = f13 f14 c8

# The#0 presence#1 of#2 activating#3 mutations#4 has#5 been#6 demonstrated#7 in#8 the#9 TSH#10 -#11 R#12 gene#13 as#14 well#15 as#16 in#17 the#18 Gs#19 alpha#20 protein#21 gene#22 in#23 thyroid#24 toxic#25 adenoma#26 resulting#27 in#28 the#29 constitutive#30 activation#31 of#32 the#33 cAMP#34 pathway#35 and#36 it#37 has#38 been#39 hypothesised#40 that#41 these#42 genetic#43 alterations#44 may#45 play#46 a#47 causative#48 role#49 in#50 the#51 disease#52 .#53

f15:[{activating_mutations#3:presence#1},has_been_demonstrated_in#5,tsh_-_r_gene#10]
f16:[{activating_mutations#3:presence#1},has_been_demonstrated_in#5,gs_alpha_protein_gene#19]
f17:[{activating_mutations#3:presence#1},resulting_in#27,{camp_pathway#34:constitutive_activation#30}]
f18:[NIL,it_has_been_hypothesised_that#37,NIL]
f19:[genetic_alterations#43,may_play#45,causative_role#48]
c9:[gs_alpha_protein_gene#19,in#23,thyroid_toxic_adenoma#24]
c10:[causative_role#48,in#50,disease#52]
stmt9 = f15 f16 f17 f18 f19 c9 c10

# However#0 ,#1 recent#2 observations#3 suggest#4 more#5 caution#6 in#7 accepting#8 such#9 a#10 hypothesis#11 .#12

f20:[{NIL#-1:recent_observations#2},suggest#4,NIL]
f21:[{caution#6:recent_observations#2},in_accepting#7,{NIL#-1:hypothesis#11}]
stmt10 = f20 f21

# The#0 presence#1 of#2 activating#3 TSH#4 -#5 R#6 mutations#7 has#8 also#9 been#10 demonstrated#11 in#12 differentiated#13 thyroid#14 carcinomas#15 .#16

f22:[{activating_tsh_-_r_mutations#3:presence#1},has_also_been_demonstrated_in#8,differentiated_thyroid_carcinomas#13]
stmt11 = f22

# At#0 present#1 ,#2 the#3 percentage#4 of#5 such#6 a#7 modification#8 is#9 low#10 ,#11 unless#12 referred#13 to#14 selected#15 series#16 of#17 tumours#18 .#19

f23:[{modification#8:percentage#4},is_low#9,NIL]
c11:[NIL,unless_referred_to#12,tumours#18]
stmt12 = f23 c11

# Activating#0 mutations#1 of#2 the#3 TSH#4 -#5 R#6 gene#7 have#8 been#9 detected#10 in#11 a#12 group#13 of#14 differentiated#15 carcinomas#16 with#17 high#18 basal#19 adenylyl#20 cyclase#21 activity#22 ,#23 and#24 in#25 a#26 few#27 cases#28 of#29 hyperfunctioning#30 thyroid#31 carcinoma#32 .#33

f24:[{tsh_-_r_gene#4:activating_mutations#0},have_been_detected_in#8,differentiated_carcinomas#15]
f25:[{tsh_-_r_gene#4:activating_mutations#0},have_been_detected_in#8,hyperfunctioning_thyroid_carcinoma#30]
c12:[{differentiated_carcinomas#15:activating_mutations#0},with#17,high_basal_adenylyl_cyclase_activity#18]
stmt13 = f24 f25 c12

# However#0 ,#1 the#2 role#3 of#4 the#5 TSH#6 -#7 R#8 -#9 related#10 cAMP#11 pathway#12 alterations#13 in#14 thyroid#15 transformation#16 remains#17 to#18 be#19 elucidated#20 .#21

f26:[{tsh_-_r_-_related_camp_pathway_alterations#6:role#3},remains_to_be_elucidated#17,NIL]
c13:[{tsh_-_r_-_related_camp_pathway_alterations#6:role#3},in#14,thyroid_transformation#15]
stmt14 = f26 c13

# In#0 this#1 review#2 ,#3 the#4 role#5 of#6 TSH#7 -#8 R#9 gene#10 alterations#11 in#12 benign#13 and#14 malignant#15 thyroid#16 neoplasia#17 is#18 examined#19 .#20

f27:[{tsh_-_r_gene_alterations#7:role#5},is_examined#18,NIL]
c14:[{tsh_-_r_gene_alterations#7:role#5},in#12,benign#13]
c15:[{tsh_-_r_gene_alterations#7:role#5},in#12,malignant_thyroid_neoplasia#15]
stmt15 = f27 c14 c15

# Cooccurrence#0 of#1 reduced#2 expression#3 of#4 alpha#5 -#6 catenin#7 and#8 overexpression#9 of#10 p53#11 is#12 a#13 predictor#14 of#15 lymph#16 node#17 metastasis#18 in#19 early#20 gastric#21 cancer#22 .#23

f28:[{alpha_-_catenin#5:reduced_expression#2},is#12,{lymph_node_metastasis#16:predictor#14}]
f29:[{p53#11:overexpression#9},is#12,{lymph_node_metastasis#16:predictor#14}]
c16:[lymph_node_metastasis#16,in#19,{early_gastric_cancer#20:predictor#14}]
stmt16 = f28 f29 c16

# BACKGROUND#0 AND#1 OBJECTIVES#2 :#3 Even#4 though#5 the#6 pathological#7 background#8 contributes#9 to#10 lymph#11 node#12 metastasis#13 ,#14 the#15 biological#16 characteristics#17 of#18 tumors#19 have#20 also#21 gained#22 wide#23 attention#24 .#25

f30:[pathological_background#7,contributes_to#9,lymph_node_metastasis#11]
c17:[{tumors#19:biological_characteristics#16},have_also_gained#20,wide_attention#23]
stmt17 = f30 c17

# In#0 this#1 study#2 ,#3 the#4 expression#5 of#6 the#7 cadherin#8 -#9 catenin#10 complex#11 and#12 p53#13 was#14 studied#15 in#16 early#17 gastric#18 cancer#19 .#20

f31:[{cadherin_-_catenin_complex#8:expression#5},was_studied_in#14,early_gastric_cancer#17]
f32:[{p53#13:expression#5},was_studied_in#14,early_gastric_cancer#17]
c18:[NIL,in#0,{NIL#-1:study#2}]
stmt18 = f31 f32 c18

# Their#0 correlation#1 with#2 lymph#3 node#4 metastasis#5 and#6 the#7 predictability#8 of#9 lymph#10 node#11 metastases#12 ,#13 by#14 combining#15 these#16 factors#17 ,#18 were#19 also#20 discussed#21 .#22

f33:[{NIL#-1:correlation#1},were_also_discussed#19,NIL]
f34:[{lymph_node_metastases#10:predictability#8},were_also_discussed#19,NIL]
c19:[{NIL#-1:correlation#1},with#2,lymph_node_metastasis#3]
c20:[{lymph_node_metastases#10:predictability#8},by_combining#14,{NIL#-1:factors#17}]
stmt19 = f33 f34 c19 c20

# METHODS#0 :#1 One#2 hundred#3 and#4 one#5 specimens#6 obtained#7 from#8 surgery#9 were#10 studied#11 by#12 immunohistochemistry#13 using#14 monoclonal#15 anti#16 -#17 E#18 -#19 cadherin#20 ,#21 anti#22 -#23 alpha#24 -#25 catenin#26 and#27 anti#28 -#29 p53#30 antibodies#31 .#32

f35:[specimens#6,NIL#-1,{NIL#-1:one_hundred_and_one#2}]
f36:[specimens#6,were_studied_by#10,immunohistochemistry#13]
c21:[specimens#6,obtained_from#7,surgery#9]
c22:[immunohistochemistry#13,using#14,monoclonal_anti_-_e_-_cadherin#15]
c23:[immunohistochemistry#13,using#14,anti_-_alpha_-_catenin#22]
c24:[immunohistochemistry#13,using#14,anti_-_p53_antibodies#28]
stmt20 = f35 f36 c21 c22 c23 c24

# RESULTS#0 :#1 Expression#2 of#3 E#4 -#5 cadherin#6 and#7 alpha#8 -#9 catenin#10 was#11 reduced#12 in#13 50#14 .#15 5#16 and#17 64#18 .#19 4#20 %#21 ,#22 respectively#23 .#24

f37:[{e_-_cadherin#4:expression#2},was_reduced_in#11,{NIL#-1:50_._5#14}]
f38:[{e_-_cadherin#4:expression#2},was_reduced_in#11,{NIL#-1:64_._4_%#18}]
f39:[{alpha_-_catenin#8:expression#2},was_reduced_in#11,{NIL#-1:50_._5#14}]
f40:[{alpha_-_catenin#8:expression#2},was_reduced_in#11,{NIL#-1:64_._4_%#18}]
stmt21 = f37 f38 f39 f40

# p53#0 protein#1 staining#2 was#3 positive#4 in#5 29#6 .#7 7#8 %#9 .#10

f41:[p53_protein_staining#0,was_positive_in#3,{NIL#-1:29_._7_%#6}]
stmt22 = f41

# There#0 was#1 a#2 significant#3 correlation#4 between#5 E#6 -#7 cadherin#8 and#9 alpha#10 -#11 catenin#12 expression#13 ,#14 but#15 no#16 correlation#17 was#18 found#19 between#20 p53#21 expression#22 and#23 E#24 -#25 cadherin#26 or#27 alpha#28 -#29 catenin#30 expression#31 .#32

f42:[NIL,was#1,significant_correlation#3]
f43:[NIL,no#16,correlation#17]
f44:[correlation#17,was_found_between#18,p53_expression#21]
f45:[correlation#17,was_found_between#18,e_-_cadherin#24]
f46:[correlation#17,was_found_between#18,alpha_-_catenin_expression#28]
c25:[significant_correlation#3,between#5,e_-_cadherin#6]
c26:[significant_correlation#3,between#5,alpha_-_catenin_expression#10]
stmt23 = f42 f43 f44 f45 f46 c25 c26

# A#0 reduction#1 in#2 alpha#3 -#4 catenin#5 expression#6 and#7 p53#8 overexpression#9 correlated#10 to#11 lymph#12 node#13 metastases#14 ,#15 respectively#16 .#17

f47:[{NIL#-1:reduction#1},correlated_to#10,lymph_node_metastases#12]
c27:[{NIL#-1:reduction#1},in#2,alpha_-_catenin_expression#3]
c28:[{NIL#-1:reduction#1},in#2,p53_overexpression#8]
stmt24 = f47 c27 c28

# Multivariate#0 analysis#1 showed#2 that#3 cooccurrence#4 of#5 reduced#6 expression#7 of#8 alpha#9 -#10 catenin#11 and#12 overexpression#13 of#14 p53#15 was#16 an#17 independent#18 factor#19 indicating#20 lymph#21 node#22 metastases#23 .#24

f48:[multivariate_analysis#0,showed_that#2,NIL]
f49:[{NIL#-1:cooccurrence#4},was#16,{NIL#-1:independent_factor#18}]
c29:[{NIL#-1:cooccurrence#4},of#5,{alpha_-_catenin#9:reduced_expression#6}]
c30:[{NIL#-1:cooccurrence#4},of#5,{p53#15:overexpression#13}]
c31:[{NIL#-1:independent_factor#18},indicating#20,lymph_node_metastases#21]
stmt25 = f48 f49 c29 c30 c31

# CONCLUSION#0 :#1 A#2 study#3 of#4 both#5 alpha#6 -#7 catenin#8 and#9 p53#10 expression#11 may#12 be#13 helpful#14 to#15 predict#16 lymph#17 node#18 metastases#19 in#20 early#21 gastric#22 cancer#23 .#24

f50:[{alpha_-_catenin#6:study#3},may_be_helpful_to_predict#12,lymph_node_metastases#17]
f51:[{p53_expression#10:study#3},may_be_helpful_to_predict#12,lymph_node_metastases#17]
c32:[lymph_node_metastases#17,in#20,early_gastric_cancer#21]
stmt26 = f50 f51 c32

# Proto#0 -#1 oncogene#2 N#3 -#4 myc#5 promoter#6 is#7 down#8 regulated#9 by#10 the#11 Wilms#12 '#13 tumor#14 suppressor#15 gene#16 WT1#17 .#18

f52:[proto_-_oncogene_n_-_myc_promoter#0,is_down_regulated_by#7,wilms_'_tumor_suppressor_gene_wt1#12]
stmt27 = f52

# The#0 Wilms#1 '#2 tumor#3 1#4 (#5 WT1#6 )#7 gene#8 is#9 a#10 tumor#11 suppressor#12 gene#13 that#14 encodes#15 a#16 zinc#17 -#18 finger#19 transcription#20 factor#21 .#22

f53:[wilms_'_tumor_1_(_wt1_)_gene#1,is#9,tumor_suppressor_gene#11]
c33:[tumor_suppressor_gene#11,encodes#15,zinc_-_finger_transcription_factor#17]
stmt28 = f53 c33

# WT1#0 represses#1 transcription#2 of#3 several#4 growth#5 factors#6 and#7 growth#8 factor#9 receptors#10 .#11

c34:[{growth_factors#5:wt1_represses_transcription#0},NIL#-1,NIL]
c35:[{growth_factor_receptors#8:wt1_represses_transcription#0},NIL#-1,NIL]
stmt29 = c34 c35

# The#0 N#1 -#2 myc#3 proto#4 -#5 oncogene#6 encodes#7 a#8 transcription#9 factor#10 which#11 regulates#12 cell#13 growth#14 and#15 differentiation#16 .#17

f54:[n_-_myc_proto_-_oncogene#1,encodes#7,transcription_factor#9]
c36:[transcription_factor#9,regulates#12,cell_growth#13]
c37:[transcription_factor#9,regulates#12,differentiation#16]
stmt30 = f54 c36 c37

# N#0 -#1 myc#2 is#3 coexpressed#4 with#5 WT1#6 in#7 the#8 developing#9 kidney#10 and#11 is#12 overexpressed#13 in#14 many#15 Wilms#16 '#17 tumors#18 .#19

f55:[n_-_myc#0,is_coexpressed_with#3,wt1#6]
f56:[n_-_myc#0,is_overexpressed_in#12,wilms_'_tumors#16]
c38:[wt1#6,in#7,developing_kidney#9]
stmt31 = f55 f56 c38

# Here#0 ,#1 we#2 show#3 that#4 the#5 proto#6 -#7 oncogene#8 N#9 -#10 myc#11 promoter#12 was#13 down#14 -#15 regulated#16 by#17 WT1#18 in#19 transient#20 transfection#21 assays#22 .#23

f57:[NIL,show_that#3,NIL]
f58:[proto_-_oncogene_n_-_myc_promoter#6,was_down_-_regulated_by#13,wt1#18]
c39:[wt1#18,in#19,transient_transfection_assays#20]
stmt32 = f57 f58 c39

# However#0 ,#1 mutant#2 WT1#3 (#4 R394W#5 )#6 which#7 has#8 a#9 mutation#10 in#11 the#12 DNA#13 binding#14 domain#15 could#16 not#17 repress#18 the#19 N#20 -#21 myc#22 promoter#23 .#24

f59:[mutant_wt1_(_r394w_)#2,has#8,mutation#10]
f60:[mutant_wt1_(_r394w_)#2,could_not_repress#16,n_-_myc_promoter#20]
c40:[mutation#10,in#11,dna_binding_domain#13]
stmt33 = f59 f60 c40

# Electrophoretic#0 mobility#1 shift#2 assays#3 showed#4 that#5 the#6 oligonucleotides#7 containing#8 the#9 WT1#10 motifs#11 could#12 bind#13 recombinant#14 WT1#15 proteins#16 .#17

f61:[electrophoretic_mobility_shift_assays#0,showed_that#4,NIL]
f62:[oligonucleotides#7,could_bind#12,recombinant_wt1_proteins#14]
c41:[oligonucleotides#7,containing#8,wt1_motifs#10]
stmt34 = f61 f62 c41

# This#0 suggests#1 that#2 the#3 repression#4 of#5 the#6 N#7 -#8 myc#9 promoter#10 is#11 mediated#12 through#13 the#14 WT1#15 binding#16 sites#17 .#18

f63:[NIL,suggests_that#1,NIL]
f64:[{n_-_myc_promoter#7:repression#4},is_mediated_through#11,wt1_binding_sites#15]
stmt35 = f63 f64

# This#0 finding#1 may#2 help#3 to#4 elucidate#5 the#6 relationship#7 of#8 WT1#9 and#10 N#11 -#12 myc#13 in#14 tumorigenesis#15 and#16 renal#17 development#18 .#19

f65:[{NIL#-1:finding#1},may_help_to_elucidate#2,{wt1#9:relationship#7}]
f66:[{NIL#-1:finding#1},may_help_to_elucidate#2,{n_-_myc#11:relationship#7}]
c42:[n_-_myc#11,in#14,tumorigenesis#15]
c43:[n_-_myc#11,in#14,renal_development#17]
stmt36 = f65 f66 c42 c43

# Tumour#0 -#1 specific#2 distribution#3 of#4 BRCA1#5 promoter#6 region#7 methylation#8 supports#9 a#10 pathogenetic#11 role#12 in#13 breast#14 and#15 ovarian#16 cancer#17 .#18

f67:[{brca1_promoter_region_methylation#5:tumour_-_specific_distribution#0},supports#9,pathogenetic_role#11]
c44:[pathogenetic_role#11,in#13,breast#14]
c45:[pathogenetic_role#11,in#13,ovarian_cancer#16]
stmt37 = f67 c44 c45

# The#0 role#1 of#2 BRCA1#3 in#4 sporadic#5 breast#6 and#7 ovarian#8 cancers#9 remains#10 elusive#11 .#12

f68:[{brca1#3:role#1},remains_elusive#10,NIL]
f69:[{ovarian_cancers#8:role#1},remains_elusive#10,NIL]
stmt38 = f68 f69

# Direct#0 involvement#1 of#2 BRCA1#3 in#4 the#5 development#6 of#7 breast#8 and#9 ovarian#10 cancer#11 is#12 suggested#13 by#14 the#15 finding#16 that#17 the#18 BRCA1#19 promoter#20 region#21 CpG#22 island#23 is#24 methylated#25 in#26 a#27 proportion#28 of#29 breast#30 and#31 ovarian#32 cancers#33 .#34

f70:[{brca1#3:direct_involvement#0},is_suggested_by#12,{NIL#-1:finding#16}]
f71:[brca1_promoter_region_cpg_island#19,is_methylated_in#24,{breast#30:proportion#28}]
f72:[brca1_promoter_region_cpg_island#19,is_methylated_in#24,{ovarian_cancers#32:proportion#28}]
c46:[{brca1#3:direct_involvement#0},in#4,{breast#8:development#6}]
c47:[{brca1#3:direct_involvement#0},in#4,{ovarian_cancer#10:development#6}]
stmt39 = f70 f71 f72 c46 c47

# The#0 aim#1 of#2 this#3 study#4 was#5 to#6 compare#7 the#8 incidence#9 of#10 BRCA1#11 promoter#12 region#13 methylation#14 in#15 tumours#16 in#17 which#18 loss#19 of#20 BRCA1#21 has#22 been#23 shown#24 to#25 play#26 a#27 role#28 in#29 pathogenesis#30 (#31 breast#32 and#33 ovarian#34 carcinomas#35 )#36 with#37 the#38 incidence#39 in#40 tumours#41 in#42 which#43 BRCA1#44 is#45 unlikely#46 to#47 play#48 a#49 role#50 in#51 pathogenesis#52 .#53

f73:[{study#4:aim#1},was_to_compare#5,{brca1_promoter_region_methylation#11:incidence#9}]
f74:[{brca1#21:loss#19},has_been_shown_to_play_a_role_in#22,pathogenesis#30]
f75:[{brca1#21:loss#19},has_been_shown_to_play_a_role_in#22,breast_and_ovarian_carcinomas#32]
f76:[brca1#44,is_unlikely_to_play_a_role_in#45,pathogenesis#52]
c48:[brca1_promoter_region_methylation#11,in#15,tumours#16]
c49:[{brca1#21:loss#19},in#17,tumours#16]
c50:[pathogenesis#30,with#37,incidence#39]
c51:[incidence#39,in#40,tumours#41]
c52:[brca1#44,in#42,tumours#41]
stmt40 = f73 f74 f75 f76 c48 c49 c50 c51 c52

# Promoter#0 region#1 hypermethylation#2 was#3 significantly#4 more#5 common#6 (#7 P#8 <#9 0#10 .#11 008#12 )#13 in#14 breast#15 and#16 ovarian#17 cancer#18 (#19 6#20 /#21 38#22 tumours#23 methylated#24 )#25 than#26 in#27 colon#28 cancer#29 (#30 0#31 /#32 35#33 tumours#34 methylated#35 )#36 or#37 in#38 leukaemias#39 (#40 0#41 /#42 19#43 samples#44 methylated#45 )#46 .#47

f77:[promoter_region_hypermethylation#0,was_significantly_more_common_(_p_<_0_._008_)_in#3,breast#15]
f78:[promoter_region_hypermethylation#0,was_significantly_more_common_(_p_<_0_._008_)_in#3,ovarian_cancer#17]
c53:[ovarian_cancer#17,6_/_38_tumours_methylated#20,NIL]
c54:[ovarian_cancer#17,than_in#26,colon_cancer#28]
c55:[ovarian_cancer#17,than_in#26,leukaemias#39]
c56:[colon_cancer#28,0_/_35_tumours_methylated#31,NIL]
c57:[leukaemias#39,0_/_19_samples_methylated#41,NIL]
stmt41 = f77 f78 c53 c54 c55 c56 c57

# The#0 restriction#1 of#2 BRCA1#3 promoter#4 region#5 hypermethylation#6 to#7 breast#8 and#9 ovarian#10 cancer#11 is#12 consistent#13 with#14 a#15 pathogenetic#16 role#17 of#18 BRCA1#19 promoter#20 methylation#21 in#22 these#23 tumours#24 .#25

f79:[{brca1_promoter_region_hypermethylation#3:restriction#1},is_consistent_with#12,{brca1_promoter_methylation#19:pathogenetic_role#16}]
c58:[{brca1_promoter_region_hypermethylation#3:restriction#1},to#7,breast#8]
c59:[{brca1_promoter_region_hypermethylation#3:restriction#1},to#7,ovarian_cancer#10]
c60:[brca1_promoter_methylation#19,in#22,tumours#24]
stmt42 = f79 c58 c59 c60

# We#0 suggest#1 that#2 the#3 rarity#4 of#5 observed#6 BRCA1#7 mutations#8 in#9 sporadic#10 breast#11 and#12 ovarian#13 cancer#14 is#15 due#16 to#17 the#18 greater#19 likelihood#20 of#21 BRCA1#22 inactivation#23 by#24 non#25 -#26 mutational#27 mechanisms#28 such#29 as#30 methylation#31 .#32

f80:[NIL,suggest_that#1,NIL]
f81:[{brca1_mutations#7:rarity#4},is_due_to#15,{brca1_inactivation#22:likelihood#20}]
f82:[non_-_mutational_mechanisms#25,such_as#29,methylation_.#31]
c61:[brca1_mutations#7,in#9,sporadic_breast#10]
c62:[brca1_mutations#7,in#9,ovarian_cancer#13]
c63:[brca1_inactivation#22,by#24,non_-_mutational_mechanisms#25]
c64:[brca1_inactivation#22,by#24,methylation#31]
stmt43 = f80 f81 f82 c61 c62 c63 c64

# Regulation#0 of#1 the#2 resident#3 chromosomal#4 copy#5 of#6 c#7 -#8 myc#9 by#10 c#11 -#12 Myb#13 is#14 involved#15 in#16 myeloid#17 leukemogenesis#18 .#19

f83:[{NIL#-1:regulation#0},is_involved_in#14,myeloid_leukemogenesis#17]
c65:[{NIL#-1:regulation#0},of#1,{c_-_myc#7:resident_chromosomal_copy#3}]
c66:[{c_-_myc#7:resident_chromosomal_copy#3},by#10,c_-_myb#11]
stmt44 = f83 c65 c66

# c#0 -#1 myb#2 is#3 a#4 frequent#5 target#6 of#7 retroviral#8 insertional#9 mutagenesis#10 in#11 murine#12 leukemia#13 virus#14 -#15 induced#16 myeloid#17 leukemia#18 .#19

f84:[c_-_myb#0,is#3,{retroviral_insertional_mutagenesis#8:frequent_target#5}]
c67:[retroviral_insertional_mutagenesis#8,in#11,murine_leukemia_virus_-_induced_myeloid_leukemia#12]
stmt45 = f84 c67

# Induction#0 of#1 the#2 leukemogenic#3 phenotype#4 is#5 generally#6 associated#7 with#8 inappropriate#9 expression#10 of#11 this#12 transcriptional#13 regulator#14 .#15

f85:[leukemogenic_phenotype#3,is_generally_associated_with#5,{transcriptional_regulator#13:inappropriate_expression#9}]
stmt46 = f85

# Despite#0 intensive#1 investigations#2 ,#3 the#4 target#5 genes#6 of#7 c#8 -#9 myb#10 that#11 are#12 specifically#13 involved#14 in#15 development#16 of#17 these#18 myeloid#19 lineage#20 neoplasms#21 are#22 still#23 unknown#24 .#25

f86:[{c_-_myb#8:target_genes#5},are_specifically_involved_in#12,{myeloid_lineage_neoplasms#19:development#16}]
f87:[{c_-_myb#8:target_genes#5},are_still_unknown#22,intensive_investigations#1]
c68:[NIL,despite#0,intensive_investigations#1]
stmt47 = f86 f87 c68

# In#0 vitro#1 assays#2 have#3 indicated#4 that#5 c#6 -#7 myc#8 may#9 be#10 a#11 target#12 gene#13 of#14 c#15 -#16 Myb#17 ;#18 however#19 ,#20 regulation#21 of#22 the#23 resident#24 chromosomal#25 gene#26 has#27 not#28 yet#29 been#30 demonstrated#31 .#32

f88:[in_vitro_assays#0,have_indicated_that#3,NIL]
f89:[c_-_myc#6,may_be#9,{c_-_myb#15:target_gene#12}]
f90:[{resident_chromosomal_gene#24:regulation#21},has_not_yet_been_demonstrated#27,{c_-_myb#15:target_gene#12}]
stmt48 = f88 f89 f90

# To#0 address#1 this#2 question#3 further#4 ,#5 we#6 analyzed#7 the#8 expression#9 of#10 c#11 -#12 myc#13 in#14 a#15 myeloblastic#16 cell#17 line#18 ,#19 M1#20 ,#21 expressing#22 a#23 conditionally#24 active#25 c#26 -#27 Myb#28 -#29 estrogen#30 receptor#31 fusion#32 protein#33 (#34 MybER#35 )#36 .#37

f91:[{NIL#-1:question#3},to_address#0,NIL]
f92:[NIL,analyzed#7,{c_-_myc#11:expression#9}]
f93:[NIL,expressing#22,c_-_myb_-_estrogen_receptor_fusion_protein#26]
f94:[NIL,expressing#22,myber#35]
c69:[c_-_myc#11,in#14,myeloblastic_cell_line#16]
c70:[c_-_myc#11,in#14,m1#20]
stmt49 = f91 f92 f93 f94 c69 c70

# Activation#0 of#1 MybER#2 both#3 prevented#4 the#5 growth#6 arrest#7 induced#8 by#9 interleukin#10 -#11 6#12 (#13 IL#14 -#15 6#16 )#17 and#18 rapidly#19 restored#20 c#21 -#22 myc#23 expression#24 in#25 nearly#26 terminal#27 differentiated#28 cells#29 that#30 had#31 been#32 exposed#33 to#34 IL#35 -#36 6#37 for#38 3#39 days#40 .#41s

f95:[{myber#2:activation#0},prevented#4,growth_arrest#6]
f96:[{myber#2:activation#0},rapidly_restored#19,c_-_myc_expression#21]
c71:[growth_arrest#6,induced_by#8,interleukin_-_6#10]
c72:[growth_arrest#6,induced_by#8,il_-_6#14]
c73:[c_-_myc_expression#21,in#25,terminal_differentiated_cells#27]
c74:[terminal_differentiated_cells#27,had_been_exposed_to#31,il_-_6#35]
c75:[il_-_6#35,for#38,{NIL#-1:3_days#39}]
stmt50 = f95 f96 c71 c72 c73 c74 c75

# Restoration#0 occurred#1 in#2 the#3 presence#4 of#5 a#6 protein#7 synthesis#8 inhibitor#9 but#10 not#11 after#12 a#13 transcriptional#14 block#15 ,#16 indicating#17 that#18 c#19 -#20 myc#21 is#22 a#23 direct#24 ,#25 transcriptionally#26 regulated#27 target#28 of#29 c#30 -#31 Myb#32 .#33

f97:[restoration#0,indicating_that#17,transcriptional_block#14]
f98:[c_-_myc#19,is#22,{c_-_myb#30:regulated_target#27}]
c76:[restoration#0,occurred_in#1,{protein_synthesis_inhibitor#7:presence#4}]
c77:[restoration#0,not_after#11,transcriptional_block#14]
stmt51 = f97 f98 c76 c77

# c#0 -#1 myc#2 is#3 a#4 major#5 target#6 that#7 transduces#8 Myb#9 '#10 s#11 proliferative#12 signal#13 ,#14 as#15 shown#16 by#17 the#18 ability#19 of#20 a#21 c#22 -#23 Myc#24 -#25 estrogen#26 receptor#27 fusion#28 protein#29 alone#30 to#31 also#32 reverse#33 growth#34 arrest#35 in#36 this#37 system#38 .#39

f99:[c_-_myc#0,is#3,{NIL#-1:major_target#5}]
c78:[{NIL#-1:major_target#5},transduces#8,{proliferative_signal#12:major_target#5}]
c79:[{NIL#-1:major_target#5},shown_by#16,{c_-_myc_-_estrogen_receptor_fusion_protein#22:ability#19}]
c80:[{NIL#-1:major_target#5},reverse#33,growth_arrest#34]
c81:[growth_arrest#34,in#36,{NIL#-1:system#38}]
stmt52 = f99 c78 c79 c80 c81

# To#0 investigate#1 the#2 possibility#3 that#4 this#5 regulatory#6 connection#7 contributes#8 to#9 Myb#10 '#11 s#12 oncogenicity#13 ,#14 we#15 expressed#16 a#17 dominant#18 negative#19 Myb#20 in#21 the#22 myeloid#23 leukemic#24 cell#25 line#26 RI#27 -#28 4#29 -#30 11#31 .#32

f100:[NIL,to_investigate#0,{NIL#-1:possibility#3}]
f101:[{NIL#-1:regulatory_connection#6},contributes_to#8,{myb#10:oncogenicity#13}]
f102:[NIL,expressed#16,{dominant_negative_myb#18:oncogenicity#13}]
c82:[dominant_negative_myb#18,in#21,{myeloid_leukemic_cell_line_ri_-_4_-_11#23:oncogenicity#13}]
stmt53 = f100 f101 f102 c82

# In#0 this#1 cell#2 line#3 ,#4 c#5 -#6 myb#7 is#8 activated#9 by#10 insertional#11 mutagenesis#12 and#13 cannot#14 be#15 effectively#16 down#17 regulated#18 by#19 cytokine#20 .#21

f103:[c_-_myb#5,is_activated_by#8,insertional_mutagenesis#11]
f104:[c_-_myb#5,cannot_be_effectively_down_regulated_by#14,cytokine#20]
c83:[NIL,in#0,cell_line#2]
stmt54 = f103 f104 c83

# Myb#0 '#1 s#2 ability#3 to#4 regulate#5 c#6 -#7 myc#8 '#9 s#10 expression#11 was#12 also#13 demonstrated#14 in#15 these#16 cells#17 ,#18 showing#19 a#20 mechanism#21 through#22 which#23 the#24 proto#25 -#26 oncogene#27 c#28 -#29 myb#30 can#31 exert#32 its#33 oncogenic#34 potential#35 in#36 myeloid#37 lineage#38 hematopoietic#39 cells#40 .#41

f105:[{myb#0:ability#3},was_also_demonstrated_in#12,cells#17]
f106:[{myb#0:ability#3},showing#19,mechanism#21]
f107:[proto_-_oncogene_c_-_myb#25,can_exert#31,oncogenic_potential#34]
c84:[{myb#0:ability#3},to_regulate#4,c_-_myc_'_s_expression#6]
c85:[NIL,through#22,mechanism#21]
c86:[oncogenic_potential#34,in#36,myeloid_lineage_hematopoietic_cells#37]
stmt55 = f105 f106 f107 c84 c85 c86

# Adenovirus#0 -#1 mediated#2 gene#3 transfer#4 of#5 endostatin#6 in#7 vivo#8 results#9 in#10 high#11 level#12 of#13 transgene#14 expression#15 and#16 inhibition#17 of#18 tumor#19 growth#20 and#21 metastases#22 .#23

f108:[{endostatin#6:adenovirus_-_mediated_gene_transfer#0},results_in#9,{transgene_expression#14:high_level#11}]
f109:[{endostatin#6:adenovirus_-_mediated_gene_transfer#0},results_in#9,{tumor_growth#19:inhibition#17}]
f110:[{endostatin#6:adenovirus_-_mediated_gene_transfer#0},results_in#9,{metastases#22:inhibition#17}]
c87:[endostatin#6,in#7,vivo#8]
stmt56 = f108 f109 f110 c87

# Inhibition#0 of#1 angiogenesis#2 has#3 been#4 shown#5 to#6 be#7 an#8 effective#9 strategy#10 in#11 cancer#12 therapy#13 in#14 mice#15 .#16

f111:[{angiogenesis#2:inhibition#0},has_been_shown_to_be#3,{cancer_therapy#12:effective_strategy#9}]
c88:[cancer_therapy#12,in#14,mice#15]
stmt57 = f111 c88

# However#0 ,#1 its#2 widespread#3 application#4 has#5 been#6 hampered#7 by#8 difficulties#9 in#10 the#11 large#12 -#13 scale#14 production#15 of#16 the#17 antiangiogenic#18 proteins#19 .#20

f112:[{NIL#-1:widespread_application#3},has_been_hampered_by#5,{NIL#-1:difficulties#9}]
c89:[{NIL#-1:difficulties#9},in#10,{antiangiogenic_proteins#18:large_-_scale_production#12}]
stmt58 = f112 c89

# This#0 limitation#1 may#2 be#3 resolved#4 by#5 in#6 vivo#7 delivery#8 and#9 expression#10 of#11 the#12 antiangiogenic#13 genes#14 .#15

f113:[{NIL#-1:limitation#1},may_be_resolved_by#2,{antiangiogenic_genes#13:in_vivo_delivery#6}]
f114:[{NIL#-1:limitation#1},may_be_resolved_by#2,{antiangiogenic_genes#13:expression#10}]
stmt59 = f113 f114

# We#0 have#1 constructed#2 a#3 recombinant#4 adenovirus#5 that#6 expresses#7 murine#8 endostatin#9 that#10 is#11 biologically#12 active#13 both#14 in#15 vitro#16 ,#17 as#18 determined#19 in#20 endothelial#21 cell#22 proliferation#23 assays#24 ,#25 and#26 in#27 vivo#28 ,#29 by#30 suppression#31 of#32 angiogenesis#33 induced#34 by#35 vascular#36 endothelial#37 growth#38 factor#39 165#40 .#41

f115:[NIL,have_constructed#1,recombinant_adenovirus#4]
c90:[recombinant_adenovirus#4,expresses#7,murine_endostatin#8]
c91:[murine_endostatin#8,is_biologically_active_both#11,in_vitro#15]
c92:[murine_endostatin#8,is_biologically_active_both#11,in_vivo#27]
c93:[in_vitro#15,as_determined_in#18,endothelial_cell_proliferation_assays#21]
c94:[in_vivo#27,by#30,{angiogenesis#33:suppression#31}]
c95:[{angiogenesis#33:suppression#31},induced_by#34,vascular_endothelial_growth_factor_165#36]
stmt60 = f115 c90 c91 c92 c93 c94 c95

# Persistent#0 high#1 serum#2 levels#3 of#4 endostatin#5 (#6 605#7 -#8 1740#9 ng#10 /#11 ml#12 ;#13 mean#14 ,#15 936#16 ng#17 /#18 ml#19 )#20 were#21 achieved#22 after#23 systemic#24 administration#25 of#26 the#27 vector#28 to#29 nude#30 mice#31 ,#32 which#33 resulted#34 in#35 significant#36 reduction#37 of#38 the#39 growth#40 rates#41 and#42 the#43 volumes#44 of#45 JC#46 breast#47 carcinoma#48 and#49 Lewis#50 lung#51 carcinoma#52 (#53 P#54 less#55 than#56 0#57 .#58 001#59 and#60 P#61 less#62 than#63 0#64 .#65 05#66 ,#67 respectively#68 )#69 .#70

f116:[{endostatin#5:persistent_high_serum_levels#0},NIL#-1,{NIL#-1:605_-_1740_ng_/_ml#7}]
f117:[{endostatin#5:persistent_high_serum_levels#0},NIL#-1,{NIL#-1:936_ng_/_ml#16}]
f118:[{endostatin#5:persistent_high_serum_levels#0},were_achieved_after#21,{vector_to_nude_mice#28:systemic_administration#24}]
f119:[p#54,less_than#55,{NIL#-1:0_._001#57}]
f120:[p#61,less_than#62,{NIL#-1:0_._05#64}]
c96:[{vector_to_nude_mice#28:systemic_administration#24},resulted_in#34,{growth_rates#40:significant_reduction#36}]
c97:[{vector_to_nude_mice#28:systemic_administration#24},resulted_in#34,{jc_breast_carcinoma#46:significant_reduction#36}]
c98:[{vector_to_nude_mice#28:systemic_administration#24},resulted_in#34,{lewis_lung_carcinoma#50:significant_reduction#36}]
stmt61 = f116 f117 f118 f119 f120 c96 c97 c98

# In#0 addition#1 ,#2 the#3 endostatin#4 vector#5 treatment#6 completely#7 prevented#8 the#9 formation#10 of#11 pulmonary#12 micrometastases#13 in#14 Lewis#15 lung#16 carcinoma#17 (#18 P#19 =#20 0#21 .#22 0001#23 )#24 .#25

f121:[endostatin_vector_treatment#4,completely_prevented#7,{pulmonary_micrometastases#12:formation#10}]
c99:[pulmonary_micrometastases#12,in#14,lewis_lung_carcinoma#15]
c100:[p#19,=#20,{NIL#-1:0_._0001#21}]
stmt62 = f121 c99 c100

# Immunohistochemical#0 staining#1 of#2 the#3 tumors#4 demonstrated#5 a#6 decreased#7 number#8 of#9 blood#10 vessels#11 in#12 the#13 treatment#14 group#15 versus#16 the#17 controls#18 .#19

f122:[{tumors#4:immunohistochemical_staining#0},demonstrated#5,{blood_vessels#10:decreased_number#7}]
c101:[blood_vessels#10,in#12,treatment_group#14]
c102:[treatment_group#14,versus#16,controls#18]
stmt63 = f122 c101 c102

# In#0 conclusion#1 ,#2 the#3 present#4 study#5 clearly#6 demonstrates#7 the#8 potential#9 of#10 vector#11 -#12 mediated#13 antiangiogenic#14 gene#15 therapy#16 as#17 a#18 component#19 in#20 cancer#21 therapy#22 .#23

f123:[{NIL#-1:present_study#4},clearly_demonstrates#6,{vector_-_mediated_antiangiogenic_gene_therapy#11:potential#9}]
c103:[{vector_-_mediated_antiangiogenic_gene_therapy#11:potential#9},as#17,{cancer_therapy#21:component#19}]
stmt64 = f123 c103

# High#0 frequency#1 of#2 hypermethylation#3 at#4 the#5 14#6 -#7 3#8 -#9 3#10 sigma#11 locus#12 leads#13 to#14 gene#15 silencing#16 in#17 breast#18 cancer#19 .#20

f124:[{hypermethylation#3:high_frequency#0},leads_to#13,gene_silencing#15]
c104:[{hypermethylation#3:high_frequency#0},at#4,14_-_3_-_3_sigma_locus#6]
c105:[gene_silencing#15,in#17,breast_cancer#18]
stmt65 = f124 c104 c105

# Expression#0 of#1 14#2 -#3 3#4 -#5 3#6 final#7 sigma#8 (#9 final#10 sigma#11 )#12 is#13 induced#14 in#15 response#16 to#17 DNA#18 damage#19 ,#20 and#21 causes#22 cells#23 to#24 arrest#25 in#26 G#27 (#28 2#29 )#30 .#31

f125:[{14_-_3_-_3_final_sigma#2:expression#0},is_induced_in_response_to#13,dna_damage#18]
f126:[{14_-_3_-_3_final_sigma#2:expression#0},causes_cells_to_arrest_in#22,g_(_2_)#27]
f127:[{final_sigma#10:expression#0},is_induced_in_response_to#13,dna_damage#18]
f128:[{final_sigma#10:expression#0},causes_cells_to_arrest_in#22,g_(_2_)#27]
stmt66 = f125 f126 f127 f128

# By#0 SAGE#1 (#2 serial#3 analysis#4 of#5 gene#6 expression#7 )#8 analysis#9 ,#10 we#11 identified#12 final#13 sigma#14 as#15 a#16 gene#17 whose#18 expression#19 is#20 7#21 -#22 fold#23 lower#24 in#25 breast#26 carcinoma#27 cells#28 than#29 in#30 normal#31 breast#32 epithelium#33 .#34

f129:[NIL,identified#12,final_sigma#13]
f130:[{gene#17:expression#19},is_7_-_fold_lower_in#20,breast_carcinoma_cells#26]
c106:[NIL,by#0,sage_(_serial_analysis_of_gene_expression_)_analysis#1]
c107:[final_sigma#13,as#15,gene#17]
c108:[breast_carcinoma_cells#26,than_in#29,normal_breast_epithelium#31]
stmt67 = f129 f130 c106 c107 c108

# We#0 verified#1 this#2 finding#3 by#4 Northern#5 blot#6 analysis#7 .#8

f131:[NIL,verified#1,{NIL#-1:finding#3}]
c109:[NIL,by#4,northern_blot_analysis#5]
stmt68 = f131 c109

# Remarkably#0 ,#1 final#2 sigma#3 mRNA#4 was#5 undetectable#6 in#7 45#8 of#9 48#10 primary#11 breast#12 carcinomas#13 .#14

f132:[final_sigma_mrna#2,was_undetectable_in#5,{48_primary_breast_carcinomas#10:45#8}]
stmt69 = f132

# Genetic#0 alterations#1 at#2 final#3 sigma#4 such#5 as#6 loss#7 of#8 heterozygosity#9 were#10 rare#11 (#12 1#13 /#14 20#15 informative#16 cases#17 )#18 ,#19 and#20 no#21 mutations#22 were#23 detected#24 (#25 0#26 /#27 34#28 )#29 .#30

f133:[genetic_alterations#0,were_rare#10,NIL]
f134:[mutations#22,were_detected#23,NIL]
c110:[genetic_alterations#0,at#2,final_sigma#3]
c111:[genetic_alterations#0,at#2,{heterozygosity#9:loss#7}]
c112:[mutations#22,no#21,mutations#22]
stmt70 = f133 f134 c110 c111 c112

# On#0 the#1 other#2 hand#3 ,#4 hypermethylation#5 of#6 CpG#7 islands#8 in#9 the#10 final#11 sigma#12 gene#13 was#14 detected#15 in#16 91#17 %#18 (#19 75#20 /#21 82#22 )#23 of#24 breast#25 tumors#26 and#27 was#28 associated#29 with#30 lack#31 of#32 gene#33 expression#34 .#35

f135:[{cpg_islands#7:hypermethylation#5},was_detected_in#14,{breast_tumors#25:91_%_(_75_/_82_)#17}]
f136:[{cpg_islands#7:hypermethylation#5},was_associated_with#28,{gene_expression#33:lack#31}]
c113:[cpg_islands#7,in#9,final_sigma_gene#11]
stmt71 = f135 f136 c113

# Hypermethylation#0 of#1 final#2 sigma#3 is#4 functionally#5 important#6 ,#7 because#8 treatment#9 of#10 final#11 sigma#12 -#13 non#14 -#15 expressing#16 breast#17 cancer#18 cell#19 lines#20 with#21 the#22 drug#23 5#24 -#25 aza#26 -#27 2#28 '#29 -#30 deoxycytidine#31 resulted#32 in#33 demethylation#34 of#35 the#36 gene#37 and#38 synthesis#39 of#40 final#41 sigma#42 mRNA#43 .#44

f137:[{final_sigma#2:hypermethylation#0},is_functionally_important#4,NIL]
f138:[{final_sigma_-_non_-_expressing_breast_cancer_cell_lines#11:treatment#9},resulted_in#32,{gene#37:demethylation#34}]
f139:[{final_sigma_-_non_-_expressing_breast_cancer_cell_lines#11:treatment#9},resulted_in#32,{final_sigma_mrna#41:synthesis#39}]
c114:[{final_sigma_-_non_-_expressing_breast_cancer_cell_lines#11:treatment#9},with#21,drug_5_-_aza_-_2_'_-_deoxycytidine#23]
stmt72 = f137 f138 f139 c114

# Breast#0 cancer#1 cells#2 lacking#3 final#4 sigma#5 expression#6 showed#7 increased#8 number#9 of#10 chromosomal#11 breaks#12 and#13 gaps#14 when#15 exposed#16 to#17 gamma#18 -#19 irradiation#20 .#21

f140:[breast_cancer_cells#0,showed#7,{chromosomal_breaks#11:increased_number#8}]
f141:[breast_cancer_cells#0,showed#7,{gaps#14:increased_number#8}]
c115:[breast_cancer_cells#0,lacking#3,final_sigma_expression#4]
c116:[breast_cancer_cells#0,exposed_to#16,gamma_-_irradiation#18]
stmt73 = f140 f141 c115 c116

# Therefore#0 ,#1 it#2 is#3 possible#4 that#5 loss#6 of#7 final#8 sigma#9 expression#10 contributes#11 to#12 malignant#13 transformation#14 by#15 impairing#16 the#17 G#18 (#19 2#20 )#21 cell#22 cycle#23 checkpoint#24 function#25 ,#26 thus#27 allowing#28 an#29 accumulation#30 of#31 genetic#32 defects#33 .#34

f142:[NIL,it_is_possible_that#2,NIL]
f143:[{final_sigma_expression#8:loss#6},contributes_to#11,malignant_transformation#13]
f144:[{final_sigma_expression#8:loss#6},allowing#28,{genetic_defects#32:accumulation#30}]
c117:[NIL,by_impairing#15,g_(_2_)_cell_cycle_checkpoint_function#18]
stmt74 = f142 f143 f144 c117

# Hypermethylation#0 and#1 loss#2 of#3 final#4 sigma#5 expression#6 are#7 the#8 most#9 consistent#10 molecular#11 alterations#12 in#13 breast#14 cancer#15 identified#16 so#17 far#18 .#19

f145:[hypermethylation#0,are#7,{molecular_alterations#11:most_consistent#9}]
f146:[{final_sigma_expression#4:loss#2},are#7,{molecular_alterations#11:most_consistent#9}]
c118:[molecular_alterations#11,in#13,breast_cancer#14]
c119:[breast_cancer#14,identified_so_far#16,breast_cancer#14]
stmt75 = f145 f146 c118 c119

# Reduced#0 oncogenicity#1 of#2 p190#3 Bcr#4 /#5 Abl#6 F#7 -#8 actin#9 -#10 binding#11 domain#12 mutants#13 .#14

c120:[{p190_bcr_/_abl_f_-_actin_-_binding_domain_mutants#3:reduced_oncogenicity#0},NIL#-1,NIL]
stmt76 = c120

# The#0 deregulated#1 Bcr#2 /#3 Abl#4 tyrosine#5 kinase#6 is#7 responsible#8 for#9 the#10 development#11 of#12 Philadelphia#13 (#14 Ph#15 )#16 -#17 positive#18 leukemia#19 in#20 humans#21 .#22

f147:[deregulated_bcr_/_abl_tyrosine_kinase#1,is_responsible_for#7,{philadelphia_(_ph_)_-_positive_leukemia#13:development#11}]
c121:[philadelphia_(_ph_)_-_positive_leukemia#13,in#20,{humans#21:development#11}]
stmt77 = f147 c121

# To#0 investigate#1 the#2 significance#3 of#4 the#5 C#6 -#7 terminal#8 Abl#9 actin#10 -#11 binding#12 domain#13 within#14 Bcr#15 /#16 Abl#17 p190#18 in#19 the#20 development#21 of#22 leukemia#23 /#24 lymphoma#25 in#26 vivo#27 ,#28 mutant#29 p190#30 DNA#31 constructs#32 were#33 used#34 to#35 generate#36 transgenic#37 mice#38 .#39

f148:[NIL,to_investigate#0,{c_-_terminal_abl_actin_-_binding_domain#6:significance#3}]
f149:[mutant_p190_dna_constructs#29,were_used_to_generate#33,transgenic_mice#37]
c122:[{c_-_terminal_abl_actin_-_binding_domain#6:significance#3},within#14,bcr_/_abl_p190#15]
c123:[bcr_/_abl_p190#15,in#19,{leukemia_/_lymphoma#23:development#21}]
c124:[leukemia_/_lymphoma#23,in#26,vivo#27]
stmt78 = f148 f149 c122 c123 c124

# Eight#0 founder#1 and#2 progeny#3 mice#4 of#5 5#6 different#7 lines#8 were#9 monitored#10 for#11 leukemogenesis#12 .#13

f150:[{founder#1:eight#0},were_monitored_for#9,leukemogenesis#12]
f151:[{different_lines#7:progeny_mice#3},were_monitored_for#9,leukemogenesis#12]
stmt79 = f150 f151

# Latency#0 was#1 markedly#2 increased#3 and#4 occurrence#5 decreased#6 in#7 the#8 p190#9 del#10 C#11 lines#12 as#13 compared#14 with#15 nonmutated#16 p190#17 BCR#18 /#19 ABL#20 transgenics#21 .#22

f152:[{NIL#-1:latency#0},was_markedly_increased#1,NIL]
f153:[{NIL#-1:occurrence#5},decreased_in#6,p190_del_c_lines#9]
c125:[p190_del_c_lines#9,as_compared_with#13,nonmutated_p190_bcr_/_abl_transgenics#16]
stmt80 = f152 f153 c125

# Western#0 blot#1 analysis#2 of#3 involved#4 hematologic#5 tissues#6 of#7 the#8 p190#9 del#10 C#11 transgenics#12 with#13 end#14 -#15 stage#16 disease#17 showed#18 high#19 -#20 level#21 expression#22 of#23 the#24 transgene#25 and#26 tyrosine#27 phosphorylation#28 of#29 Cbl#30 and#31 Hef1#32 /#33 Cas#34 ,#35 proteins#36 previously#37 shown#38 to#39 be#40 affected#41 by#42 Bcr#43 /#44 Abl#45 .#46

f154:[{NIL#-1:western_blot_analysis#0},showed#18,{transgene#25:high_-_level_expression#19}]
f155:[{NIL#-1:western_blot_analysis#0},showed#18,{cbl_and_hef1_/_cas#30:tyrosine_phosphorylation#27}]
f156:[proteins#36,previously_shown_to_be_affected_by#37,bcr_/_abl#43]
c126:[{NIL#-1:western_blot_analysis#0},of#3,{p190_del_c_transgenics#9:involved_hematologic_tissues#4}]
c127:[{NIL#-1:western_blot_analysis#0},with#13,end_-_stage_disease#14]
stmt81 = f154 f155 f156 c126 c127

# These#0 results#1 show#2 that#3 the#4 actin#5 -#6 binding#7 domain#8 of#9 Abl#10 enhances#11 leukemia#12 development#13 but#14 does#15 not#16 appear#17 to#18 be#19 an#20 absolute#21 requirement#22 for#23 leukemogenesis#24 .#25

f157:[{NIL#-1:results#1},show_that#2,NIL]
f158:[{abl#10:actin_-_binding_domain#5},enhances#11,leukemia_development#12]
f159:[{abl#10:actin_-_binding_domain#5},does_not_appear_to_be#15,{leukemogenesis#24:absolute_requirement#21}]
stmt82 = f157 f158 f159

# Building#0 the#1 vertebrate#2 vasculature#3 :#4 research#5 is#6 going#7 swimmingly#8 .#9

f160:[NIL,building#0,vertebrate_vasculature#2]
f161:[{NIL#-1:research#5},is_going_swimmingly#6,NIL]
stmt83 = f160 f161

# The#0 vertebrate#1 vasculature#2 develops#3 in#4 remarkably#5 similar#6 fashion#7 in#8 all#9 vertebrates#10 .#11

f162:[vertebrate_vasculature#1,develops_in#3,{vertebrates#10:remarkably_similar_fashion#5}]
stmt84 = f162

# A#0 cohort#1 of#2 unspecified#3 mesodermal#4 cells#5 differentiates#6 into#7 primitive#8 endothelial#9 cells#10 ,#11 which#12 migrate#13 to#14 and#15 occupy#16 positions#17 within#18 the#19 stereotypical#20 blueprint#21 of#22 the#23 primitive#24 vasculature#25 .#26

f163:[{unspecified_mesodermal_cells#3:cohort#1},differentiates_into#6,primitive_endothelial_cells#8]
c128:[primitive_endothelial_cells#8,migrate_to#13,{NIL#-1:positions#17}]
c129:[primitive_endothelial_cells#8,occupy#16,{NIL#-1:positions#17}]
c130:[primitive_endothelial_cells#8,within#18,{primitive_vasculature#24:stereotypical_blueprint#20}]
stmt85 = f163 c128 c129 c130

# Once#0 in#1 position#2 ,#3 these#4 cells#5 coalesce#6 and#7 form#8 cords#9 ,#10 which#11 lumenize#12 and#13 become#14 ensheathed#15 by#16 supporting#17 pericytes#18 and#19 smooth#20 muscle#21 cells#22 .#23

f164:[cells#5,coalesce#6,cords#9]
f165:[cells#5,form#8,cords#9]
c131:[NIL,once_in_position#0,NIL]
c132:[cords#9,lumenize#12,NIL]
c133:[cords#9,become_ensheathed#14,NIL]
c134:[NIL,by_supporting#16,pericytes#18]
c135:[NIL,by_supporting#16,smooth_muscle_cells#20]
stmt86 = f164 f165 c131 c132 c133 c134 c135

# This#0 primitive#1 vascular#2 network#3 is#4 extensively#5 remodeled#6 in#7 some#8 places#9 ,#10 and#11 expanded#12 by#13 sprouting#14 in#15 others#16 .#17

f166:[primitive_vascular_network#1,is_extensively_remodeled_in#4,{NIL#-1:places#9}]
f167:[primitive_vascular_network#1,expanded_by_sprouting_in#12,{NIL#-1:others#16}]
stmt87 = f166 f167

# Various#0 studies#1 using#2 the#3 mouse#4 ,#5 quail#6 /#7 chick#8 ,#9 and#10 frog#11 have#12 uncovered#13 a#14 number#15 of#16 signals#17 that#18 guide#19 these#20 complex#21 processes#22 but#23 many#24 gaps#25 still#26 exist#27 in#28 our#29 understanding#30 of#31 the#32 mechanisms#33 by#34 which#35 the#36 embryonic#37 vasculature#38 is#39 built#40 .#41

f168:[{NIL#-1:various_studies#0},have_uncovered#12,{NIL#-1:signals#17}]
f169:[{NIL#-1:gaps#25},still_exist_in#26,{mechanisms#33:understanding#30}]
f170:[embryonic_vasculature#37,is_built#39,NIL]
c136:[{NIL#-1:various_studies#0},using#2,mouse#4]
c137:[{NIL#-1:various_studies#0},using#2,quail_/_chick#6]
c138:[{NIL#-1:various_studies#0},using#2,frog#11]
c139:[{NIL#-1:signals#17},guide#19,{NIL#-1:complex_processes#21}]
c140:[NIL,by#34,mechanisms#33]
stmt88 = f168 f169 f170 c136 c137 c138 c139 c140

# Because#0 many#1 questions#2 will#3 require#4 in#5 vivo#6 studies#7 to#8 be#9 properly#10 addressed#11 ,#12 the#13 zebrafish#14 ,#15 with#16 its#17 unique#18 accessibility#19 to#20 analysis#21 by#22 combined#23 embryological#24 ,#25 molecular#26 ,#27 and#28 genetic#29 methods#30 ,#31 should#32 prove#33 invaluable#34 in#35 identifying#36 new#37 molecules#38 involved#39 in#40 blood#41 vessel#42 development#43 and#44 integrating#45 pathways#46 that#47 influence#48 embryonic#49 blood#50 vessel#51 formation#52 .#53

f171:[{NIL#-1:questions#2},will_require#3,in_vivo_studies#5]
f172:[in_vivo_studies#5,to_be_properly_addressed#8,NIL]
f173:[{zebrafish#14:unique_accessibility#18},should_prove_invaluable_in_identifying#32,molecules#38]
f174:[molecular#26,should_prove_invaluable_in_identifying#32,molecules#38]
f175:[genetic_methods#29,should_prove_invaluable_in_identifying#32,molecules#38]
c141:[{zebrafish#14:unique_accessibility#18},to_analysis_by#20,combined_embryological#23]
c142:[molecules#38,involved_in#39,blood_vessel_development#41]
c143:[molecules#38,integrating#45,pathways#46]
c144:[pathways#46,influence#48,embryonic_blood_vessel_formation#49]
stmt89 = f171 f172 f173 f174 f175 c141 c142 c143 c144

# [#0 Interleukin#1 -#2 18#3 and#4 new#5 drugs#6 .#7 Protective#8 effect#9 against#10 tumor#11 growth#12 and#13 infections#14 ]#15 .#16

c145:[interleukin_-_18#1,NIL#-1,NIL]
c146:[drugs#6,NIL#-1,NIL]
c147:[{NIL#-1:protective_effect#8},against#10,tumor_growth#11]
c148:[{NIL#-1:protective_effect#8},against#10,infections#14]
stmt90 = c145 c146 c147 c148

# IL#0 -#1 18#2 ,#3 originally#4 identified#5 as#6 interferon#7 -#8 gamma#9 inducing#10 factor#11 (#12 IGIF#13 )#14 ,#15 is#16 related#17 to#18 the#19 IL#20 -#21 1#22 family#23 in#24 terms#25 of#26 its#27 structure#28 as#29 well#30 as#31 its#32 processing#33 ,#34 receptor#35 ,#36 signal#37 transduction#38 pathway#39 and#40 pro#41 -#42 inflammatory#43 properties#44 .#45

f176:[il_-_18#0,is_related_to#16,{il_-_1_family#20:structure#28}]
f177:[il_-_18#0,is_related_to#16,{il_-_1_family#20:processing#33}]
f178:[il_-_18#0,is_related_to#16,{il_-_1_family#20:receptor#35}]
f179:[il_-_18#0,is_related_to#16,signal_transduction_pathway#37]
f180:[il_-_18#0,is_related_to#16,pro_-_inflammatory_properties#41]
c149:[il_-_18#0,originally_identified_as#4,interferon_-_gamma_inducing_factor#7]
c150:[il_-_18#0,originally_identified_as#4,igif#13]
stmt91 = f176 f177 f178 f179 f180 c149 c150

# IL#0 -#1 18#2 is#3 also#4 functionally#5 related#6 to#7 IL#8 -#9 12#10 ,#11 as#12 it#13 induces#14 the#15 production#16 of#17 Th1#18 cytokines#19 and#20 participates#21 in#22 cell#23 -#24 mediated#25 immune#26 cytotoxicity#27 .#28

f181:[il_-_18#0,is_also_functionally_related_to#3,il_-_12#8]
f182:[il_-_18#0,induces#14,{th1_cytokines#18:production#16}]
f183:[il_-_18#0,participates_in#21,cell_-_mediated_immune_cytotoxicity#23]
stmt92 = f181 f182 f183

# A#0 summary#1 is#2 made#3 of#4 recent#5 advances#6 in#7 the#8 understanding#9 of#10 IL#11 -#12 18#13 structure#14 ,#15 processing#16 ,#17 receptor#18 expression#19 and#20 immunoregulatory#21 functions#22 .#23

f184:[{NIL#-1:summary#1},is_made_of#2,{NIL#-1:recent_advances#5}]
c151:[{NIL#-1:recent_advances#5},in#7,{NIL#-1:understanding#9}]
c152:[{NIL#-1:understanding#9},of#10,{il_-_18#11:structure#14}]
c153:[{NIL#-1:understanding#9},of#10,{il_-_18#11:processing#16}]
c154:[{NIL#-1:understanding#9},of#10,{il_-_18#11:receptor_expression#18}]
c155:[{NIL#-1:understanding#9},of#10,{il_-_18#11:immunoregulatory_functions#21}]
stmt93 = f184 c151 c152 c153 c154 c155

# It#0 focuses#1 on#2 the#3 role#4 of#5 IL#6 -#7 18#8 modulation#9 in#10 tumours#11 ,#12 infections#13 and#14 autoimmune#15 and#16 inflammatory#17 diseases#18 .#19

f185:[NIL,it_focuses_on#0,{il_-_18_modulation#6:role#4}]
c156:[il_-_18_modulation#6,in#10,tumours#11]
c157:[il_-_18_modulation#6,in#10,infections#13]
c158:[il_-_18_modulation#6,in#10,autoimmune#15]
c159:[il_-_18_modulation#6,in#10,inflammatory_diseases#17]
stmt94 = f185 c156 c157 c158 c159

# A#0 small#1 peptide#2 derived#3 from#4 Flt#5 -#6 1#7 (#8 VEGFR#9 -#10 1#11 )#12 functions#13 as#14 an#15 angiogenic#16 inhibitor#17 .#18

c160:[peptide#2,derived_from#3,flt_-_1_(_vegfr_-_1_)_functions#5]
c161:[peptide#2,as#14,angiogenic_inhibitor#16]
stmt95 = c160 c161

# Vascular#0 endothelial#1 growth#2 factor#3 (#4 VEGF#5 )#6 is#7 an#8 angiogenic#9 stimulator#10 which#11 functions#12 through#13 two#14 endothelial#15 specific#16 tyrosine#17 kinase#18 receptors#19 ,#20 Flt#21 -#22 1#23 and#24 Flk#25 -#26 1#27 .#28

f186:[vascular_endothelial_growth_factor#0,is#7,angiogenic_stimulator#9]
f187:[vegf#5,is#7,angiogenic_stimulator#9]
c162:[angiogenic_stimulator#9,functions_through#12,{endothelial_specific_tyrosine_kinase_receptors#15:two#14}]
c163:[angiogenic_stimulator#9,functions_through#12,flt_-_1#21]
c164:[angiogenic_stimulator#9,functions_through#12,flk_-_1#25]
stmt96 = f186 f187 c162 c163 c164

# In#0 this#1 work#2 ,#3 we#4 show#5 that#6 an#7 11#8 -#9 amino#10 acid#11 peptide#12 derived#13 from#14 the#15 second#16 immunoglobulin#17 -#18 like#19 domain#20 of#21 Flt#22 -#23 1#24 functions#25 as#26 an#27 angiogenic#28 inhibitor#29 in#30 chick#31 chorioallantoic#32 membrane#33 and#34 inhibited#35 VEGF#36 -#37 induced#38 vascular#39 permeability#40 in#41 Miles#42 '#43 assay#44 without#45 binding#46 to#47 VEGF#48 directly#49 .#50

f188:[NIL,in#0,{NIL#-1:work#2}]
f189:[NIL,show_that#5,NIL]
f190:[11_-_amino_acid_peptide#8,induced#38,{miles_'_assay#42:vascular_permeability#39}]
c165:[11_-_amino_acid_peptide#8,derived_from#13,{flt_-_1_functions#22:second_immunoglobulin_-_like_domain#16}]
c166:[11_-_amino_acid_peptide#8,as#26,angiogenic_inhibitor#28]
c167:[angiogenic_inhibitor#28,in#30,chick_chorioallantoic_membrane#31]
c168:[angiogenic_inhibitor#28,in#30,inhibited_vegf_-#35]
c169:[NIL,without_binding_to#45,vegf#48]
stmt97 = f188 f189 f190 c165 c166 c167 c168 c169

# Circular#0 dichroism#1 and#2 nuclear#3 magnetic#4 resonance#5 analyses#6 indicate#7 that#8 this#9 peptide#10 forms#11 a#12 stable#13 extended#14 structure#15 in#16 solution#17 ,#18 presumably#19 beta#20 -#21 sheet#22 structure#23 and#24 is#25 most#26 likely#27 existing#28 as#29 a#30 dimer#31 .#32

f191:[circular_dichroism#0,indicate_that#7,NIL]
f192:[nuclear_magnetic_resonance_analyses#3,indicate_that#7,NIL]
f193:[peptide#10,forms#11,{solution#17:stable_extended_structure#13}]
f194:[peptide#10,forms#11,{solution#17:beta_-_sheet_structure#20}]
f195:[peptide#10,is_most_likely_existing_as#25,dimer#31]
stmt98 = f191 f192 f193 f194 f195

# Our#0 results#1 suggest#2 that#3 this#4 small#5 peptide#6 functions#7 as#8 an#9 angiogenic#10 inhibitor#11 by#12 inhibiting#13 VEGF#14 function#15 through#16 a#17 non#18 -#19 VEGF#20 binding#21 mechanism#22 .#23

f196:[{NIL#-1:results#1},suggest_that#2,NIL]
f197:[peptide_functions#6,function_through#15,non_-_vegf_binding_mechanism#18]
c170:[peptide_functions#6,as#8,angiogenic_inhibitor#10]
c171:[peptide_functions#6,by_inhibiting#12,vegf_function#14]
stmt99 = f196 f197 c170 c171

# Coexpression#0 of#1 vascular#2 endothelial#3 growth#4 factor#5 and#6 p53#7 protein#8 in#9 squamous#10 cell#11 carcinoma#12 of#13 the#14 esophagus#15 .#16

c172:[{vascular_endothelial_growth_factor#2:coexpression#0},in#9,{esophagus#15:squamous_cell_carcinoma#10}]
c173:[{p53_protein#7:coexpression#0},in#9,{esophagus#15:squamous_cell_carcinoma#10}]
stmt100 = c172 c173

